However, the percentages of CD86+MHC IIhi DCs in tumor-infiltrating lymphocytes (TILs) were highest in mice treated with CTGF/E7 DNA vaccine and everolimus (G7) (G1, 9.9 ± 1.4%; G2, 14.6 ± 0.3%; G3, 8.4 ± 0.6%; G4, 7.4 ± 0.3%; G5, 7.2 ± 0.4%; G6, 12.7 ± 0.6%; G7, 16.4 ± 0.3%; G3, 7.6 ± 0.3%; p = 0.027, Figure 7G). The gene discussed is CD86; the disease is neoplasm.